FAQ

We are a biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized, point-of-care CAR-T manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. More information is available in our company fact sheet and brochure.

Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. Please see Our Story for more on this.

Galapagos is headquartered in Mechelen, Belgium and has facilities throughout Europe and in the US. Addresses and contact info here.

Please visit our Contact page.

We gather all our resources in our Download Center. If you cannot find what you are looking for there, please reach out to our Corporate Communications team via the Contact form. If you are a journalist, we invite you to have a look at our Newsroom.

Please visit our Clinical Trials Portal. If you don’t find your answer there, please contact Medical Information via our Contact form.

Yes, please find it here.

We post our Annual CSR report on our Sustainability section. Scroll down to the bottom of the page for the Reports.

You’ll find our Charters and Codes on our Corporate Governance section.